Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Brander who wrote (2424)	5/12/1998 5:04:00 PM
From: Todd N	Read Replies (1) \| Respond to of 9523

Brad Just curious if you have noticed any increase in the amount of scripts for MUSE in your practice. In your experience, do any of the patients who don't achieve success with Viagra seek another treatment such as MUSE? I own both PFE and Vivus (mostly PFE), and am very bullish on both. The VVUS bulls are anticipating an increase in scripts for MUSE, due to the increased awareness that Viagra brought about, and new scripts for people who may have failed on Viagra. This coat-tail effect has yet to be seen as of the last IMS numbers, as users appearantly try Viaga first. Any light you can shed on this matter would be appreciated. Todd

To: Brander who wrote (2424)	5/13/1998 3:08:00 PM
From: Logain Ablar	Read Replies (1) \| Respond to of 9523

Brad: No doubt a block buster greater than even what the company hopped for. We'll have to wait and see how the drug is paid for. This will be a big issue with the insurers and HMO's who play part fo the role of gate keeper. (All above comments are redundant to what has been posted). One has to remember that it is the employer and ultimately the employee that the insurer / HMO collects their revenue from to pay for the drug. A hard balance in our society but better than the socialistic systems of Europe. Tim